| Name | Title | Contact Details |
|---|
As a non-profit business league, we`re funded by the healthcare industry to make the system work better for everyone. We do this work because we envision a future where providers can focus on delivering care. Health plans can focus on serving their customers. Purchasers can feel confident they`re getting the most value for their money. And where patients can ultimately get the best possible care at an affordable price. What brings us together at IHA is our passion to create a system where patients always receive the best possible care. We leave our egos at the door. We embrace the tough conversations. And we never lose sight of driving results. United by our values of Collaboration, Candor and Impact, our dedicated team works every day in support of high-quality, efficient care for all Californians. Our 40-member board of directors includes leaders from health plans, physician organizations, hospitals, health systems, purchasers, consumer groups, universities, and pharmaceutical and technology companies.
Since 1965, Telecare has been committed to making a difference in the lives of people with serious mental illness. We believe in Recovery, and in the human ability and desire to reach its full potential. We have created an environment that puts the
Humans across the globe and of all walks of life want to live at their personal best, and are seeking more natural alternatives to feeling their best and getting the most out of life. Today, they are discovering the answer through natural cannabinoid products. At the same time, science and technology are unlocking the future potential of cannabinoids. We believe that cannabinoids, when used responsibly, have the power to enhance the full spectrum of well-being and to help us live healthier and happier lives. Parallel is improving the well-being of our consumers today through our proprietary, innovative brands, while planting seeds for the future through our robust innovation and high bar for business standards.
BLOSSOM SOUTH is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.